MannKind Corporation to Present at H.C. Wainwright 21st Annual Global Investment Conference

WESTLAKE VILLAGE, Calif., Aug. 30, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation MNKD, a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced today that it will be featured as a presenting company at the H.C. Wainwright 21^st Annual Global Investment Conference on Monday, September 9, 2019 at 12:05 pm (ET) at the Lotte New York Palace Hotel in New York City. 

Michael Castagna, Chief Executive Officer, of MannKind Corporation, will provide an overview of the Company's business during the live presentation.  Steven B. Binder, Chief Financial Officer, will participate in one-on-one meetings with investors who are registered to attend the conference. 

The presentation will be webcast live.  Interested parties can access a link to the live webcast of the presentation from the News & Events section of the Company's website at http://www.mannkindcorp.com.  The webcast replay will remain available for 14 days following the live presentation.

About MannKind Corporation
MannKind Corporation MNKD focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only orally inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. The Company also employs field sales and medical representatives across the U.S. For further information, visit www.mannkindcorp.com.

Company Contact:
Rose Alinaya
Investor Relations
818-661-5000
ir@mannkindcorp.com